DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID)

Objective

Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for two forms of SCID (SCID-X1 and ADA SCID) has shown significant safety and efficacy in correcting the immunodeficiency and allowing children to live normal lives. Proof of concept of gene therapy for 3 other SCID forms has also been shown by members of the proposed SCIDNET consortium and is ready for translation into clinical trials. We are therefore in a position whereby, over the next 4 years, we can offer gene therapy as a curative option for over 80% of all forms of SCID in Europe. Importantly for 1 of these conditions (ADA SCID) we will undertake clinical trials that will lead to marketing authorisation of the gene therapy product as a licensed medicine. In addition, we will investigate the future technologies that will improve the safety and efficacy of gene therapy for SCID.

Our proposal addresses an unmet clinical need in SCID, which is classified as a rare disease according to EU criteria (EC regulation No. 141/2000). The proposal also addresses the need to develop an innovative treatment such as gene therapy from early clinical trials though to a licensed medicinal product through involvement with regulatory agencies and is in keeping with the ambitions of the IRDiRC. The lead ADA SCID programme has Orphan Drug Designation and clinical trial design is assisted by engagement with the European medicines Agency. The ADA SCID trial will act as a paradigm for the development of the technologies and processes that will allow gene therapy for not only SCID, but also other bone marrow disorders, to become authorised genetic medicines in the future.

Field of science

• /medical and health sciences/medical biotechnology/cells technologies/stem cells
• /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
• /medical and health sciences/clinical medicine/transplantation
• /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
• /medical and health sciences/basic medicine/immunology

Programme(s)

• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-14-2015 - New therapies for rare diseases

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

Coordinator

Participants (11)